Associated tags: Blood, Cancer stem cell, IBS, Intraoperative blood salvage, Dentistry, Medical imaging, MAT, CE, Safety, Collection, Metastasis
Locations:
FDA,
Cancer,
Prostate,
Cell,
Risk,
Blood,
Filter,
CE marking,
Cytokine,
Trauma,
Immunosuppression,
Intensive care medicine,
MD,
Carcinoma,
PILOT,
Pain management,
Patient,
Lung,
Teaching hospital,
Clinical trial,
IBS,
Medical imaging Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.
Key Points:
- Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.
- Following these positive results, Company has initiated process to receive CE Mark in Europe and FDA conformity in the US.
- Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, announced today excellent top-line results from the REMOVE certification study, a confirmatory open-label, multicenter clinical study, that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries.
- CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from the blood of cancer patients.
Cancer,
Safety,
Blood,
Immunosuppression,
Intensive care medicine,
Pain management,
Patient,
Teaching hospital,
Lymphocyte,
IBS,
Medical device Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
Key Points:
- Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
- The symposium will take place in Bologna, Italy between April 18 – 20, 2024.
- CATUVAB® aims to ensure that cancer patients receive their own blood, minimizing the risks associated with allogenic (donor) blood transfusions.
- Following the positive study outcome, CATUVAB® is aimed for approval in the EU and US in accordance with Medical Device Regulations.
Retrieved on:
Wednesday, December 20, 2023
FDA,
Ovary,
Blood,
Transfusion-related acute lung injury,
Certification,
Risk,
Lung,
Patient,
Hospital,
Regulation,
Cell,
Cancer,
Carcinoma,
IBS,
Immunosuppression,
Infection,
Metastasis,
Lymphocyte,
Medical imaging,
Medical device,
Epithelial cell adhesion molecule Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, today announced that the last patient in its certification study REMOVE has successfully completed the trial.
Key Points:
- Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, today announced that the last patient in its certification study REMOVE has successfully completed the trial.
- REMOVE, a confirmation open-label multicenter clinical study, enrolled 130 patients being one of the largest studies assessing a medical device for the removal of tumor cells in an intraoperative blood salvage (IBS) procedure.
- CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from patient blood during cancer surgeries.
- This procedure aims to be an easy-to-implement method that combines trifunctional antibody that aggregates the tumor cells and lymphocytes with current filter technologies and intraoperative blood salvage devices available at nearly all hospitals.
Retrieved on:
Sunday, November 27, 2022
Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB, is pleased to announce the formation of its Scientific Advisory Board (SAB) comprising world-leading experts and key opinion leaders in the field of perioperative patient care, de-risking operative interventions, blood management and regulatory affairs.
Key Points:
- Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB, is pleased to announce the formation of its Scientific Advisory Board (SAB) comprising world-leading experts and key opinion leaders in the field of perioperative patient care, de-risking operative interventions, blood management and regulatory affairs.
- CATUVAB is a novel approach designed to be a safe and cost-effective way to reliably remove tumor cells from autologous blood.
- Composition of the Lindis Blood Care Scientific Advisory Board:
Neil Blumberg, MD, is Professor of the Department of Pathology and Laboratory Medicine at the University of Rochester Medical Center and Director of the Transfusion Medicine Unit, Blood Bank, and Stem Cell Storage Facility.
- Lindis Blood Care is a medical technology company developing the medical device CATUVAB.
Retrieved on:
Wednesday, February 9, 2022
Trial of the century,
LANXESS,
QIAGEN,
Cancer,
Safety,
Collection,
TAG Tegernsee Immobilien und Beteiligung,
Federal Ministry of Health (Germany),
Chemistry,
Schwarz Gruppe,
Oncology,
Federal Ministry for Economic Affairs and Energy,
SAP,
Blood transfusion,
Recurrence,
FDA,
Blood,
Wilh. Wilhelmsen,
European,
Life expectancy,
Metastasis,
EUR,
Certification,
LBC,
New Senior Investment Group,
Regional development,
Risk,
Technology,
Schufa,
Investitionsbank Berlin,
Committee on European Affairs and Oversight of the European Funds,
Neoplasm,
ILB,
Vector Informatik,
Economy,
Deutsche Bank,
Business Growth Fund,
Boehringer Ingelheim,
EWE,
Deutsche Post,
BASF,
MAT,
CE,
Gold standard,
IBS,
Partnership,
Medical device,
Medical imaging,
Fine chemical,
Economics,
PHOENIX,
Lindis Blood Care,
Brandenburg Kapital GMBH / ILB,
LINDIS BLOOD CARE,
BRANDENBURG KAPITAL GMBH / ILB "This investment comes at an exciting time for Lindis Blood Care, and we are grateful for the continued support and trust that our investors have placed in our innovative approach," commented Dr. Franzpeter Bracht, founder and Managing Director of Lindis Blood Care.
Key Points:
- "This investment comes at an exciting time for Lindis Blood Care, and we are grateful for the continued support and trust that our investors have placed in our innovative approach," commented Dr. Franzpeter Bracht, founder and Managing Director of Lindis Blood Care.
- With its medical device CATUVAB(R), Lindis Blood Care aims to set a new Gold Standard in cancer patient blood management by reliably removing tumor cells from patient blood collected during surgery.
- Lindis Blood Care is a medical technology company developing the medical device CATUVAB(R).
- To date, external investors have injected more than EUR 4 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds.
Retrieved on:
Wednesday, November 10, 2021
Safety,
BioMed Central,
MAT,
MD,
Cytokine,
Epithelial cell adhesion molecule,
Immune system,
Department,
Blood,
CE,
LDF,
Carcinoma,
EC,
Intensive care medicine,
Anesthesiology,
IBS,
Metastasis,
Hospital,
IL-6,
Collection,
Lymphocyte,
IL-8,
Patient,
Risk,
Gold,
Medical imaging Key Points:
- The publication "Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device - a pilot study" can be accessed online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555247/ .
- CATUVAB(R) consists of a trifunctional antibody, that aggregates the tumor cells and lymphocytes, and a leukocyte depletion filter (LDF).
- Results of the study showed, that after the CATUVAB(R) procedure, no malignant cells were detected in the final erythrocyte concentrates.
- The product and process can be integrated easily into everyday clinical practice and become part of contemporary "patient blood management".
With the removal of these tumor cells, it should be possible to safely return the patient's own blood to them during the surgery.
Key Points:
- With the removal of these tumor cells, it should be possible to safely return the patient's own blood to them during the surgery.
- Otherwise, the risk of metastasis from tumor cells being released into the blood during the procedure is assessed as too high.
- Lindis Blood Care's approach has provided proof-of-concept both in vitro and in an initial clinical study with 15 patients.
- It consists of a trifunctional antibody and filter that enables tumor cells to be removed reliably from surgical blood using the standard MAT procedure.
